Cost-effectiveness of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) testing and isolation strategies in nursing homes

被引:2
|
作者
Bartsch, Sarah M. [1 ,2 ,3 ]
Weatherwax, Colleen [1 ,2 ,3 ]
Martinez, Marie F. [1 ,2 ,3 ]
Chin, Kevin L. [1 ,2 ,3 ]
Wasserman, Michael R. [4 ,5 ]
Singh, Raveena D. [6 ]
Heneghan, Jessie L. [1 ,2 ,3 ]
Gussin, Gabrielle M. [6 ]
Scannell, Sheryl A. [1 ,2 ,3 ]
White, Cameron [1 ,2 ,3 ]
Leff, Bruce [7 ]
Huang, Susan S. [6 ]
Lee, Bruce Y. [1 ,2 ,3 ,8 ]
机构
[1] CUNY, Ctr Adv Technol & Commun Hlth CATCH, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
[2] CUNY, Publ Hlth Informat Computat & Operat Res PHICOR, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
[3] CUNY, Artificial Intelligence Modeling Informat Nutr Gui, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
[4] Los Angeles Jewish Home, Reseda, CA USA
[5] Calif Assoc Long Term Care Med, Santa Clarita, CA USA
[6] Univ Calif Irvine, Div Infect Dis, Sch Med, Irvine, CA USA
[7] Johns Hopkins Univ, Ctr Transformat Geriatr Res, Div Geriatr Med, Sch Med, Baltimore, MD USA
[8] CUNY, New York City Pandem Response Inst PRI, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
基金
美国医疗保健研究与质量局;
关键词
COVID-19; EFFICACY; OUTCOMES;
D O I
10.1017/ice.2024.9
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: Nursing home residents may be particularly vulnerable to coronavirus disease 2019 (COVID-19). Therefore, a question is when and how often nursing homes should test staff for COVID-19 and how this may change as severe acute respiratory coronavirus virus 2 (SARS-CoV-2) evolves.Design: We developed an agent-based model representing a typical nursing home, COVID-19 spread, and its health and economic outcomes to determine the clinical and economic value of various screening and isolation strategies and how it may change under various circumstances.Results: Under winter 2023-2024 SARS-CoV-2 omicron variant conditions, symptom-based antigen testing averted 4.5 COVID-19 cases compared to no testing, saving $191 in direct medical costs. Testing implementation costs far outweighed these savings, resulting in net costs of $990 from the Centers for Medicare & Medicaid Services perspective, $1,545 from the third-party payer perspective, and $57,155 from the societal perspective. Testing did not return sufficient positive health effects to make it cost-effective [$50,000 per quality-adjusted life-year (QALY) threshold], but it exceeded this threshold in >= 59% of simulation trials. Testing remained cost-ineffective when routinely testing staff and varying face mask compliance, vaccine efficacy, and booster coverage. However, all antigen testing strategies became cost-effective (<=$31,906 per QALY) or cost saving (saving <=$18,372) when the severe outcome risk was >= 3 times higher than that of current omicron variants.Conclusions: SARS-CoV-2 testing costs outweighed benefits under winter 2023-2024 conditions; however, testing became cost-effective with increasingly severe clinical outcomes. Cost-effectiveness can change as the epidemic evolves because it depends on clinical severity and other intervention use. Thus, nursing home administrators and policy makers should monitor and evaluate viral virulence and other interventions over time.
引用
收藏
页码:754 / 761
页数:8
相关论文
共 50 条
  • [41] The emerging role of microRNAs in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
    Mirzaei, Rasoul
    Mahdavi, Farzad
    Badrzadeh, Fariba
    Hosseini-Fard, Seyed Reza
    Heidary, Maryam
    Jeda, Ali Salimi
    Mohammadi, Tayeb
    Roshani, Mahdane
    Yousefimashouf, Rasoul
    Keyvani, Hossein
    Darvishmotevalli, Mohammad
    Sani, Melika Zarei
    Karampoor, Sajad
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 90
  • [42] Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to animals: an updated review
    Sina Salajegheh Tazerji
    Phelipe Magalhães Duarte
    Parastoo Rahimi
    Fatemeh Shahabinejad
    Santosh Dhakal
    Yashpal Singh Malik
    Awad A. Shehata
    Juan Lama
    Jörn Klein
    Muhammad Safdar
    Md. Tanvir Rahman
    Krzysztof J. Filipiak
    Alfonso J. Rodríguez-Morales
    Md. Abdus Sobur
    Farrokhreza Kabir
    Bita Vazir
    Leonard Mboera
    Marco Caporale
    Md. Saiful Islam
    John H. Amuasi
    Rasha Gharieb
    Paola Roncada
    Sahar Musaad
    Bruno Tilocca
    Mohammad Kazem Koohi
    Ali Taghipour
    Ahmet Sait
    Kannan Subbaram
    Alireza Jahandideh
    Pejman Mortazavi
    Mohammad Amin Abedini
    David A. Hokey
    Unarose Hogan
    Mohamed N. F. Shaheen
    Ahmed Elaswad
    Mahmoud M. Elhaig
    Mohamed Fawzy
    Journal of Translational Medicine, 18
  • [43] An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies
    Chatterjee, Suparna
    Choudhury, Shouvik
    Das, Debaleena
    INDIAN JOURNAL OF PHARMACOLOGY, 2022, 54 (01) : 51 - 57
  • [44] A review of metallic nanostructures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
    Saraswat, Istuti
    Saha, Sarmistha
    Mishra, Anuja
    TOXICOLOGY AND ENVIRONMENTAL HEALTH SCIENCES, 2023, 15 (04) : 315 - 324
  • [45] The severe acute respiratory syndrome due to coronavirus 2 (SARS-CoV-2) infection and the climacteric woman
    Chedraui, Peter
    Perez-Lopez, Faustino R.
    CLIMACTERIC, 2020, 23 (06) : 525 - 527
  • [46] Coinfection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and Influenza: An Evolving Puzzle
    Covin, Sara
    Rutherford, George W.
    CLINICAL INFECTIOUS DISEASES, 2021, 72 (12) : E993 - E994
  • [47] Impact and cost-effectiveness of SARS-CoV-2 self-testing strategies in schools: a multicountry modelling analysis
    Chevalier, Joshua M.
    Han, Alvin X.
    Hansen, Megan A.
    Klock, Ethan
    Pandithakoralage, Hiromi
    Ockhuisen, Tom
    Girdwood, Sarah J.
    Lekodeba, Nkgomeleng A.
    de Nooy, Alexandra
    Khan, Shaukat
    Johnson, Cheryl C.
    Sacks, Jilian A.
    Jenkins, Helen E.
    Russell, Colin A.
    Nichols, Brooke E.
    BMJ OPEN, 2024, 14 (02):
  • [48] BTK inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Systematic Review
    Stack, Michael
    Sacco, Keith
    Livinski, Alicia
    Notarangelo, Luigi
    Lionakis, Michail
    JOURNAL OF CLINICAL IMMUNOLOGY, 2021, 41 (SUPPL 1) : S18 - S18
  • [49] BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review
    Stack, Michael
    Sacco, Keith
    Castagnoli, Riccardo
    Livinski, Alicia A.
    Notarangelo, Luigi D.
    Lionakis, Michail S.
    CLINICAL IMMUNOLOGY, 2021, 230
  • [50] Posterior Oropharyngeal Saliva for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
    Wong, Sally Cheuk Ying
    Tse, Herman
    Siu, Hon Kei
    Kwong, Tsz Shan
    Chu, Man Yee
    Yau, Felix Yat Sun
    Cheung, Ingrid Yu Ying
    Tse, Cindy Wing Sze
    Poon, Kin Chiu
    Cheung, Kwok Chi
    Wu, Tak Chiu
    Chan, Johnny Wai Man
    Cheuk, Wah
    Lung, David Christopher
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (11) : 2939 - 2946